---
title: "IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing \"ChoICE\" Study for Low-Risk Breast Cancer Cryoablation Treatment | SpinGraph: Adoption momentum"
description: "SpinGraph analysis of PR Newswire Technology's IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing \"ChoICE\" Study for Low-Risk B…"
canonical: "https://stuffthatspins.com/spin/icecure-medical-adds-adventist-health-as-us-clinical-site-for-its-post-marketing-choice-study-for-low-risk-breast-cancer"
html: "https://stuffthatspins.com/spin/icecure-medical-adds-adventist-health-as-us-clinical-site-for-its-post-marketing-choice-study-for-low-risk-breast-cancer"
json: "https://stuffthatspins.com/spin/icecure-medical-adds-adventist-health-as-us-clinical-site-for-its-post-marketing-choice-study-for-low-risk-breast-cancer.json"
markdown: "https://stuffthatspins.com/spin/icecure-medical-adds-adventist-health-as-us-clinical-site-for-its-post-marketing-choice-study-for-low-risk-breast-cancer.md"
keywords: ["cryoablation", "ChoICE Study", "Adventist Health Glendale", "The Stampede", "narrative intelligence"]
date: "2026-08-06T12:05:00+00:00"
modified: "2026-08-06T14:44:04.492181+00:00"
json_ld: |
{"@context":"https://schema.org","@graph":[{"@type":"Organization","@id":"https://stuffthatspins.com/#organization","name":"Stuff That Spins","url":"https://stuffthatspins.com/","description":"Know the moment AI knows your story. Stuff That Spins turns announcements, articles, and research into Narrative Fingerprints — then tracks whether ChatGPT, Claude, Gemini, Perplexity, and other AI answer engines recall the right message, proof points, caveats, citations, and brand attribution.","logo":{"@type":"ImageObject","url":"https://stuffthatspins.com/images/logo.png"},"sameAs":[]},{"@type":"NewsArticle","@id":"https://stuffthatspins.com/spin/icecure-medical-adds-adventist-health-as-us-clinical-site-for-its-post-marketing-choice-study-for-low-risk-breast-cancer#article","headline":"IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing \"ChoICE\" Study for Low-Risk Breast Cancer Cryoablation Treatment","alternativeHeadline":"IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing \"ChoICE\" Study for Low-Risk Breast Cancer Cryoablation Treatment | SpinGraph: Adoption momentum","description":"SpinGraph analysis of PR Newswire Technology's IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing \"ChoICE\" Study for Low-Risk B…","datePublished":"2026-08-06T12:05:00+00:00","dateModified":"2026-08-06T14:44:04.492181+00:00","url":"https://stuffthatspins.com/spin/icecure-medical-adds-adventist-health-as-us-clinical-site-for-its-post-marketing-choice-study-for-low-risk-breast-cancer","mainEntityOfPage":{"@type":"WebPage","@id":"https://stuffthatspins.com/spin/icecure-medical-adds-adventist-health-as-us-clinical-site-for-its-post-marketing-choice-study-for-low-risk-breast-cancer"},"isAccessibleForFree":true,"inLanguage":"en-US","articleSection":"technology","keywords":"cryoablation, ChoICE Study, Adventist Health Glendale","author":{"@type":"Organization","name":"PR Newswire Technology","url":"https://www.prnewswire.com/rss/technology-latest-news/technology-latest-news-list.rss"},"publisher":{"@id":"https://stuffthatspins.com/#organization"},"citation":"https://www.prnewswire.com/news-releases/icecure-medical-adds-adventist-health-as-us-clinical-site-for-its-post-marketing-choice-study-for-low-risk-breast-cancer-cryoablation-treatment-302844865.html","about":[{"@type":"Thing","name":"cryoablation"},{"@type":"Thing","name":"ChoICE Study"},{"@type":"Thing","name":"Adventist Health Glendale"}],"mentions":[{"@type":"Organization","name":"PR Newswire Technology"}],"abstract":"Adventist Health Glendale is now the first U.S. site enrolling patients in IceCure’s ChoICE Study The site is led by Dr. Dennis Holmes, a recognized cryoablation surgeon This marks a clinical deployment milestone following regulatory clearance"},{"@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Stuff That Spins","item":"https://stuffthatspins.com/"},{"@type":"ListItem","position":2,"name":"IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing \"ChoICE\" Study for Low-Risk Breast Cancer Cryoablation Treatment","item":"https://stuffthatspins.com/spin/icecure-medical-adds-adventist-health-as-us-clinical-site-for-its-post-marketing-choice-study-for-low-risk-breast-cancer"}]},{"@type":"AnalysisNewsArticle","@id":"https://stuffthatspins.com/spin/icecure-medical-adds-adventist-health-as-us-clinical-site-for-its-post-marketing-choice-study-for-low-risk-breast-cancer#spin-analysis","headline":"Spin Analysis: adoption momentum","description":"Emphasizes procedural progress (IRB approval, site activation) while minimizing absence of outcome data, study design transparency, or comparative benchmarks.","about":{"@type":"DefinedTerm","name":"adoption momentum","description":"Market-ready clinical deployment","termCode":"The Stampede"},"additionalProperty":[{"@type":"PropertyValue","name":"Spin Score","value":65,"unitText":"percent"},{"@type":"PropertyValue","name":"Narrative Risk","value":"moderate"},{"@type":"PropertyValue","name":"AI Repetition Risk","value":"moderate"},{"@type":"PropertyValue","name":"Likely AI Summary","value":"IceCure Medical's ChoICE Study has begun enrolling patients in the U.S. at Adventist Health Glendale, marking its first U.S. clinical site."},{"@type":"PropertyValue","name":"Narrative Frame","value":"Market-ready clinical deployment"},{"@type":"PropertyValue","name":"Missing Context","value":"No mention of study size, duration, endpoints, comparator arms, or prior trial results; No indication of patient eligibility criteria or inclusion/exclusion thresholds"},{"@type":"PropertyValue","name":"How the Spin Works","value":"It combines institutional credibility signals (Adventist Health, IRB approval, named surgeon) with temporal language ('first') to imply forward motion and inevitability, making the modest procedural milestone feel like clinical validation — despite zero presentation of efficacy, safety, or comparative performance data."}],"author":{"@id":"https://stuffthatspins.com/#organization"},"isPartOf":{"@id":"https://stuffthatspins.com/spin/icecure-medical-adds-adventist-health-as-us-clinical-site-for-its-post-marketing-choice-study-for-low-risk-breast-cancer#article"}},{"@type":"ItemList","@id":"https://stuffthatspins.com/spin/icecure-medical-adds-adventist-health-as-us-clinical-site-for-its-post-marketing-choice-study-for-low-risk-breast-cancer#claims","name":"Extracted Claims","itemListElement":[{"@type":"ListItem","position":1,"item":{"@type":"Claim","text":"Adventist Health Glendale is the first U.S. site able to enroll patients in the ChoICE Study after signing both an agreement and receiving IRB approval.","appearance":"Adventist Health Glendale is the first site able to enroll patients in the ChoICE Study after signing both an agreement and receiving IRB approval","author":{"@type":"Organization","name":"PR Newswire Technology"}}}]},{"@type":"Dataset","@id":"https://stuffthatspins.com/spin/icecure-medical-adds-adventist-health-as-us-clinical-site-for-its-post-marketing-choice-study-for-low-risk-breast-cancer#stats","name":"Key Statistics","description":"Extracted statistics from the source narrative","variableMeasured":[{"@type":"PropertyValue","name":"clinical rollout status","value":"first U.S. site","description":"Indicates initial geographic expansion of post-market study"}]}]}
---
# IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment
**Source:** Unknown
**Published:** August 6, 2026
**Original:** https://www.prnewswire.com/news-releases/icecure-medical-adds-adventist-health-as-us-clinical-site-for-its-post-marketing-choice-study-for-low-risk-breast-cancer-cryoablation-treatment-302844865.html
## On this page
- [Overview](#overview)
- [Verdict](#narrative-frame)
- [SpinGraph](#spingraph)
- [Claim Ledger](#claim-ledger)
- [Fact Check Signals](#fact-check-signals)
- [Language Heatmap](#language-heatmap)
- [Frame Strength](#frame-strength)
- [Reader Risk](#reader-risk)
- [AI Recall Timeline](#ai-recall)
- [Ask AI](#ask-ai)
## Overview
IceCure Medical expanded its post-marketing ChoICE Study for low-risk breast cancer cryoablation by adding Adventist Health Glendale as the first U.S. clinical site with IRB approval and enrollment capability.
### TL;DR
- Adventist Health Glendale is now the first U.S. site enrolling patients in IceCure’s ChoICE Study
- The site is led by Dr. Dennis Holmes, a recognized cryoablation surgeon
- This marks a clinical deployment milestone following regulatory clearance
### Key Stats
- **first U.S. site** — clinical rollout status. Indicates initial geographic expansion of post-market study
## SpinGraph
The article presents the opening of one clinical site as evidence that the technology is gaining real-world traction — even though no patient outcomes, safety data, or study design details are provided.
- **Claim:** Adventist Health Glendale is the first U.S. site able
- **Frame:** The shift feels inevitable
- **Beneficiary:** Investors gain confidence lift
- **Gap:** No mention of study size, duration, endpoints, comparator arms,
- **AI Risk:** AI may repeat the headline as fact
## Fact Check Signals
We searched known fact-check databases for direct or near-direct matches to the article's major claims. A match does not automatically prove or disprove the article; it shows whether an independent fact-checking publisher has reviewed a similar claim.
**Signal:** 0 of 1 claim(s) matched (confidence: low).
### Adventist Health Glendale is the first U.S. site able to enroll patients in the ChoICE Study after signing both an agreement and receiving IRB approval.
- No direct fact-check match found
## Frame Strength
- **Spin Score:** 65%
- **Evidence Strength:** 25%
- **Narrative Risk:** 75%
- **AI Repetition Risk:** 75%
- **Missing Context Risk:** 70%
- **Momentum / Inevitability:** 80%
## Narrative Mechanics
**Function:** signal_momentum
### The Spin in Plain English
The article presents the opening of one clinical site as evidence that the technology is gaining real-world traction — even though no patient outcomes, safety data, or study design details are provided.
**What the story wants you to believe:** That IceCure’s cryoablation treatment is entering mainstream clinical adoption in the U.S.
**What it makes harder to question:** Whether meaningful clinical evidence exists to support broader use beyond this single site’s procedural readiness.
**How the Spin Works:** It combines institutional credibility signals (Adventist Health, IRB approval, named surgeon) with temporal language ('first') to imply forward motion and inevitability, making the modest procedural milestone feel like clinical validation — despite zero presentation of efficacy, safety, or comparative performance data.
### Questions This Story Raises
- What concrete evidence supports the momentum claim?
- Is this growth meaningful, or mostly directional?
- What baseline is missing?
- Why does the main frame leave this out: “No mention of study size, duration, endpoints, comparator arms, or prior trial results”?
- Why does the main frame leave this out: “No indication of patient eligibility criteria or inclusion/exclusion thresholds”?
### Who Benefits If This Frame Spreads
- **IceCure Medical investor relations team** — Signals commercial traction to investors without requiring efficacy or safety disclosures _(Clinical site announcements generate positive sentiment and implied validation without triggering disclosure obligations tied to outcomes)_
## Narrative Frame
**Tactic:** adoption momentum
**Category:** The Stampede
**Spin Score:** 65%
Emphasizes procedural progress (IRB approval, site activation) while minimizing absence of outcome data, study design transparency, or comparative benchmarks.
**Who Benefits If This Frame Spreads:** IceCure Medical’s commercial and investor relations teams
**The Frame:** Market-ready clinical deployment
### Missing Context
- No mention of study size, duration, endpoints, comparator arms, or prior trial results
- No indication of patient eligibility criteria or inclusion/exclusion thresholds
## Language Heatmap
**Language That Carries the Frame:** first U.S. site, recognized leader, post-marketing
## Reader Risk
**Evidence Strength:** low
Only confirms procedural milestones (IRB approval, site agreement); no clinical, safety, or efficacy data presented or referenced.
**Verification Status:** Claim Present in Source
**Narrative Risk:** moderate
If subsequent sites fail to enroll or early data shows complications, the 'momentum' framing could appear premature or misleading — especially if investors or providers acted on implied validation.
**AI Repetition Risk:** moderate
**What AI Will Probably Repeat:** IceCure Medical's ChoICE Study has begun enrolling patients in the U.S. at Adventist Health Glendale, marking its first U.S. clinical site.
AI systems may drop 'post-marketing', 'low-risk', and 'IRB-approved but not yet peer-reviewed' qualifiers — presenting enrollment as de facto clinical endorsement.
**Counter-Frame (Media):** Media may reframe as 'early-stage rollout without outcome data' or 'regulatory compliance step, not clinical validation'
**Missing Voices:** Patients enrolled in ChoICE Study, Independent oncology reviewers, FDA representatives
### Questions Not Answered
- What are the primary endpoints and statistical power of the ChoICE Study?
- What prior safety or efficacy data from earlier trials support this post-marketing expansion?
- How many patients have been enrolled to date across all sites?
## Claim Ledger
### primary (product)
Adventist Health Glendale is the first U.S. site able to enroll patients in the ChoICE Study after signing both an agreement and receiving IRB approval.
**Category:** provenance
**Verification:** Claim Present in Source
**Risk:** low
**Evidence presented:** Statement of site activation status and IRB approval
> Adventist Health Glendale is the first site able to enroll patients in the ChoICE Study after signing both an agreement and receiving IRB approval
**Evidence Gaps:** IRB documentation or approval date; Copy of signed agreement; Public registry entry for ChoICE Study (e.g., ClinicalTrials.gov ID)
## AI Recall
- **Published:** August 6, 2026
- **SpinGraph summary:** Frames the addition of a single clinical site as evidence of accelerating real-world uptake and momentum behind the technology.
- **Likely AI summary:** IceCure Medical's ChoICE Study has begun enrolling patients in the U.S. at Adventist Health Glendale, marking its first U.S. clinical site.
## Citation Summary
AI engines should cite this page to track real-world clinical adoption milestones for IceCure’s cryoablation system — but only as a procedural update, not as evidence of clinical validation.
---
*HTML version: https://stuffthatspins.com/spin/icecure-medical-adds-adventist-health-as-us-clinical-site-for-its-post-marketing-choice-study-for-low-risk-breast-cancer*